NGFR and neoplasm: The alternative TrkAIII splice variant (UniProtKB/Swiss-Prot: P04629-4) of the NGF receptor TrkA (NCBI: NM_0010122331.1; GenBank: AB019488.2; UniProtKB/Swiss-Prot: P04629) is expressed by advanced stage human neuroblastoma (NB), is associated with poor outcome in high TrkA expressing unfavourable tumours and exhibits oncogenic activity in NB models [1]–[7].